- •In Spain, most patients do not achieve recommended LDLc goals.
- •This is mainly due to an insufficient intensification of LLT.
- •The misperception of physicians about the real LDLc control and underestimation of CV risk could explain this poor control.
- •Intensification of LLT is desirable to attain LDLc targets.
Background and aims
We aimed to understand the impact of physicians’ perception about LDL-cholesterol (LDLc) control on the management of patients with dyslipidemia in Spain.
We performed a cross-sectional and multicenter study, in which 435 healthcare professionals participated in face-to-face meetings, collecting qualitative and quantitative information related to hypercholesterolemia management. Additionally, aggregated anonymized data of the last 10 patients with hypercholesterolemia attended by each physician were collected.
A total of 4,010 patients (8%, 13%, 16% and 61% with low, moderate, high, and very high cardiovascular [CV] risk) were included. Physicians’ perception was that 62% of their patients attained LDLc goals (66%, 63%, 61% and 56%, for low, moderate, high and very high CV risk, respectively). However, when looking into the data only 31% (vs 62% p<0.01) of patients attained the LDLc goals (47%, 36%, 22% and 25%, respectively). Overall, 33% of patients were taking high intensity statins, 32% statin/ezetimibe, 21% low/moderate intensity statins and 4% PCSK9 inhibitors. These numbers were 38%, 45%, 8% and 6% for very high risk patients and 44%, 21%, 21% and 4% for high CV risk patients. In 32% of patients, a change in lipid lowering therapy was performed after the visit, mainly combining statins/ezetimibe (55%).
In Spain, most patients with dyslipidemia do not achieve the recommended LDLc goals because of an insufficient intensification of lipid lowering therapy. On the one hand, this is in part due to physicians misperception on preventive LDLc control and the need for repeated advice to patient, and, on the other, to the lack of patient adherence.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Atherosclerosis
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Heart disease and stroke statistics-2022 update: a report from the American heart association.Circulation. 2022; 145: e153-e639https://doi.org/10.1161/CIR.0000000000001052
- ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.Eur. Heart J. 2020; 41: 111-188https://doi.org/10.1093/eurheartj/ehz455
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.Eur. Heart J. 2017; 38: 2459-2472https://doi.org/10.1093/eurheartj/ehx144
- Cholesterol and atherosclerotic cardiovascular disease: a lifelong problem.J. Am. Heart Assoc. 2019; 8e012924https://doi.org/10.1161/JAHA.119.012924
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.Lancet. 2010; 376: 1670-1681https://doi.org/10.1016/S0140-6736(10)61350-5
- Lipid lowering in acute coronary syndrome: is treatment early enough?.JAMA. 2018; 319: 1325-1326https://doi.org/10.1001/jama.2018.2426
- Primary prevention. The cornerstone to reduce the burden of cardiovascular disease.Rev. Esp. Cardiol. 2021; 74: 827-828https://doi.org/10.1016/j.rec.2021.04.013
- Recommendations to improve lipid control. Consensus document of the Spanish Society of Cardiology.Rev. Esp. Cardiol. 2020; 73: 161-167https://doi.org/10.1016/j.rec.2019.08.012
- Recommendations to improve lipid control in primary prevention patients. A consensus document of the Spanish Society of Cardiology.REC. CardioClinics. 2021; 56: 208-217https://doi.org/10.1016/j.rccl.2021.05.002
- An innovative lipid-lowering approach to enhance attainment of low-density lipoprotein cholesterol goals.Eur. Heart. J. Acute. Cardiovasc. Care. 2020; 9: 879-887https://doi.org/10.1177/2048872620912639
- Optimal use of lipid-lowering therapy after acute coronary syndromes: a Position Paper endorsed by the International Lipid Expert Panel (ILEP).Pharmacol. Res. 2021; 166105499https://doi.org/10.1016/j.phrs.2021.105499
- Cardiovascular risk factors in Spain in the first decade of the 21st century, a pooled analysis with individual data from 11 population-based studies: the DARIOS study.Rev. Esp. Cardiol. 2011; 64: 295-304https://doi.org/10.1016/j.recesp.2010.11.005
- Achievement of low-density lipoprotein cholesterol therapeutic goal in lipid and vascular risk units of the Spanish Arteriosclerosis Society.Clín. Invest. Arterioscler. 2013; 25: 155-163https://doi.org/10.1016/j.arteri.2013.07.006
- Degree of lipid control in patients with coronary heart disease and measures adopted by physicians.REPAR study, Rev. Esp. Cardiol. 2016; 69: 931-938https://doi.org/10.1016/j.rec.2016.02.012
- Prior use of medication for primary prevention in patients with coronary syndrome.J. Prim. Care. Community. Health. 2020; 112150132720946949https://doi.org/10.1177/2150132720946949
- EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study.Eur. J. Prev. Cardiol. 2021; 28: 1279-1289https://doi.org/10.1093/eurjpc/zwaa047
- Control of LDL-C levels after an acute coronary syndrome in Spain. Are the available treatments adequately used?.Rev. Esp. Cardiol. 2021; 74: 194-196https://doi.org/10.1016/j.rec.2020.06.027
- LDL-C: lower is better for longer-even at low risk.BMC Med. 2020; 18: 320https://doi.org/10.1186/s12916-020-01792-7
- Main barriers in the management of dyslipidaemias: intolerants.Clín. Invest. Arterioscler. 2021; 33: 40-45https://doi.org/10.1016/j.arteri.2020.12.003
- A global survey of physicians' perceptions on cholesterol management: the from the Heart study.Int. J. Clin. Pract. 2007; 61: 1078-1085https://doi.org/10.1111/j.1742-1241.2007.01420.x
- Barriers to cardiovascular risk prevention and management in Germany--an analysis of the EURIKA study.Vasc. Health Risk Manag. 2012; 8: 177-186https://doi.org/10.2147/VHRM.S29915
- Dyslipidemia observatory: treatment of hypercholesterolemia in Spain, context and levers for improvement in clinical practice.Clín. Invest. Arterioscler. 2022; 34: 253-260https://doi.org/10.1016/j.arteri.2022.02.001
- Evaluation of perceptions, knowledge and compliance with guidelines in real-life practice: a survey on the under-treatment of hypercholesterolemia.Turk Kardiyol. Dernegi Arsivi. 2019; 47: 599-608https://doi.org/10.5543/tkda.2019.39293
- The reasons of poor lipid target attainment for secondary prevention in real life practice: results from EPHESUS.Int. J. Clin. Pract. 2019; 73: 1-9https://doi.org/10.1111/ijcp.13358
- Half of patients with type 2 diabetes mellitus are at very high cardiovascular risk according to the ESC/EASD: data from a large Mediterranean population.Eur. J. Prev. Cardiol. 2022; 28: e32-e34https://doi.org/10.1093/eurjpc/zwaa073
- Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American heart association and American college of cardiology.Circulation. 2019; 139: e1162-e1177https://doi.org/10.1161/CIR.0000000000000638
- Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain.DYSIS-Spain Study, Rev. Esp. Cardiol. 2011; 64: 286-294https://doi.org/10.1016/j.recesp.2010.10.030
- Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study.Eur. Heart J. 2011; 32: 2143-2152https://doi.org/10.1093/eurheartj/ehr080
- An enquiry based on a standardised questionnaire into knowledge, awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the Asia-Pacific region: the "Ten Countries Study".BMJ Open. 2017; 7e017817https://doi.org/10.1136/bmjopen-2017-017817
- Management of high-risk hypercholesterolemic patients and PCSK9 inhibitors reimbursement policies: data from a cohort of Italian hypercholesterolemic outpatients.J. Clin. Med. 2022; 11: 4701https://doi.org/10.3390/jcm11164701
- What do US physicians and patients think about lipid-lowering therapy and goals of treatment? Results from the GOULD registry.J. Am. Heart Assoc. 2021; 10e020893https://doi.org/10.1161/JAHA.120.020893
- Management of LDL-cholesterol levels in patients with diabetes mellitus in cardiology practice: real-life evidence of under-treatment from the EPHESUS registry.Eur. J. Clin. Invest. 2021; 51e13528https://doi.org/10.1111/eci.13528
- Prevalence of statin intolerance: a meta-analysis.Eur. Heart J. 2022; 43: 3213-3223https://doi.org/10.1093/eurheartj/ehac015
- Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management.Atherosclerosis. 2017; 263: 112-118https://doi.org/10.1016/j.atherosclerosis.2017.06.006
- The association between low-density lipoprotein cholesterol goal attainment, physician and patient attitudes and perceptions, and healthcare policy.J. Atherosclerosis Thromb. 2014; 21: 1044-1054https://doi.org/10.5551/jat.24158
- Low density lipoprotein cholesterol target goal attainment rate and physician perceptions about target goal achievement in Korean patients with diabetes.Diabetes Metab. J. 2011; 35: 628-636https://doi.org/10.4093/dmj.2011.35.6.628
- Clinical characteristics and unmet need among patients with atherosclerotic cardiovascular disease stratified by statin use.Am. Health. Drug. Benefits. 2016; 9: 434-444
- Determinants of treatment modification in hypercholesterolemic patients.Acta Cardiol. Sin. 2017; 33: 156-164https://doi.org/10.6515/acs20161215a
- Use of Lipoprotein(a) to improve diagnosis and management in clinical familial hypercholesterolemia.Atherosclerosis. 2023; 365: 27-33https://doi.org/10.1016/j.atherosclerosis.2022.11.020
- Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.Eur. Heart J. 2022; 43: 3925-3946https://doi.org/10.1093/eurheartj/ehac361
- Use of bempedoic acid in patients with dyslipidemia. A practical approach.Rev. Esp. Cardiol. Supl. 2021; 21: 1-7https://doi.org/10.1016/S1131-3587(21)00005-4
- Which patients could benefit from the use of bempedoic acid in clinical practice?.Rev. Esp. Cardiol. 2022; 75: 847-848https://doi.org/10.1016/j.rec.2022.05.007
- Approach to the patient with a suboptimal statin response: causes and algorithm for clinical management.J. Clin. Endocrinol. Metab. 2023; (Mar 17 Epub ahead of print)https://doi.org/10.1210/clinem/dgad153
- Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction ("Jena auf Ziel").Clin. Res. Cardiol. 2023; (Jan 5. Epub ahead of print)https://doi.org/10.1007/s00392-022-02147-3
Published online: May 11, 2023
Accepted: April 27, 2023
Received in revised form: April 26, 2023
Received: October 25, 2022
© 2023 Elsevier B.V. All rights reserved.